BR9708928A - Tratamento de asma com tnfr-ig - Google Patents

Tratamento de asma com tnfr-ig

Info

Publication number
BR9708928A
BR9708928A BR9708928-1A BR9708928A BR9708928A BR 9708928 A BR9708928 A BR 9708928A BR 9708928 A BR9708928 A BR 9708928A BR 9708928 A BR9708928 A BR 9708928A
Authority
BR
Brazil
Prior art keywords
asthma
treatment
tnfr
tnf
binding protein
Prior art date
Application number
BR9708928-1A
Other languages
English (en)
Inventor
Louis Martin Renzetti
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR9708928A publication Critical patent/BR9708928A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Patente de Invenção: <B>''TRATAMENTO DE ASMA COM TNFR-Ig''<D>. A presente invenção refere-se a um processo para combater asma com uma composição contendo uma quantidade eficaz de uma proteína de ligação TNF-alfa quimérica que compreende a parte solúvel do receptor TNF p55 e todos os domínios exceto o primeiro domínio da região constante da cadeia pesada de uma lgG1 ou lgG3 humana e ao uso de uma tal proteína de ligação TNF-alfa quimérica para a preparação de um medicamento para o tratamento de asma.
BR9708928-1A 1996-05-08 1997-05-02 Tratamento de asma com tnfr-ig BR9708928A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1684296P 1996-05-08 1996-05-08
PCT/EP1997/002256 WO1997041895A2 (en) 1996-05-08 1997-05-02 TREATMENT OF ASTHMA WITH TNFR-Ig

Publications (1)

Publication Number Publication Date
BR9708928A true BR9708928A (pt) 2000-05-09

Family

ID=21779275

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9708928-1A BR9708928A (pt) 1996-05-08 1997-05-02 Tratamento de asma com tnfr-ig

Country Status (15)

Country Link
EP (1) EP0910413A2 (pt)
JP (1) JP2000510113A (pt)
KR (1) KR20000010825A (pt)
CN (1) CN1233189A (pt)
AR (1) AR007020A1 (pt)
AU (1) AU725408B2 (pt)
BR (1) BR9708928A (pt)
CA (1) CA2253557A1 (pt)
CO (1) CO4820397A1 (pt)
HR (1) HRP970224A2 (pt)
MA (1) MA24169A1 (pt)
PE (1) PE70698A1 (pt)
TR (1) TR199802238T2 (pt)
WO (1) WO1997041895A2 (pt)
ZA (1) ZA973843B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1044267A2 (en) * 1997-12-29 2000-10-18 Regeneron Pharmaceuticals, Inc. Novel nucleic acid and polypeptide with homology to the tnf-receptors
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
US20010021380A1 (en) * 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
JP4980048B2 (ja) * 2003-02-28 2012-07-18 アレス トレーディング ソシエテ アノニム 腫瘍壊死因子結合タンパク質の液体製剤
TWI374935B (en) * 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
KR20090071652A (ko) 2006-10-20 2009-07-01 바이오겐 아이덱 엠에이 인코포레이티드 가용성 림프독소-베타-수용체를 이용한 탈수초성 장애의 치료

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1132471A3 (de) * 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
WO1994006476A1 (en) * 1992-09-15 1994-03-31 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
US5684222A (en) * 1993-01-22 1997-11-04 Ontario Cancer Institute Mutant mouse having a disrupted TNFRp55
CA2119089A1 (en) * 1993-03-29 1994-09-30 David Banner Tumor necrosis factor muteins
JPH09508140A (ja) * 1994-07-22 1997-08-19 エフ・ホフマン−ラ ロシュ アーゲー キメラｔｎｆ結合タンパク質を含有する医薬組成物
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
IL116436A (en) * 1995-12-18 2006-12-31 Yissum Res Dev Co Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND

Also Published As

Publication number Publication date
AU2776497A (en) 1997-11-26
HRP970224A2 (en) 1998-04-30
AU725408B2 (en) 2000-10-12
MA24169A1 (fr) 1997-12-31
PE70698A1 (es) 1998-11-18
CN1233189A (zh) 1999-10-27
WO1997041895A2 (en) 1997-11-13
EP0910413A2 (en) 1999-04-28
ZA973843B (en) 1997-11-10
KR20000010825A (ko) 2000-02-25
JP2000510113A (ja) 2000-08-08
CA2253557A1 (en) 1997-11-13
CO4820397A1 (es) 1999-07-28
AR007020A1 (es) 1999-10-13
WO1997041895A3 (en) 1998-03-12
TR199802238T2 (xx) 1999-02-22

Similar Documents

Publication Publication Date Title
BG109311A (en) PHARMACEUTICAL COMPOSITION, INCLUDING HUMAN ANTIBODIES CONNECTING HUMAN TNFAL, AND HIS APPLICATION
HUP9902327A3 (en) Humanized antibodies to human gp39, compositions containing and therapeutic use thereof
GB2301366A (en) Antibodies against E-selectin
WO2002043570A3 (en) METHODS FOR THE PREVENTION AND TREATMENT OF CANCER USING ANTI-C3B(i) ANTIBODIES
BRPI0108676B8 (pt) anticorpos humanizados que sequestram peptídeo amilóide beta e seus usos no tratamento de condições caracterizadas por formação de placas amiloides, bem como composição farmacêutica que compreende os referidos anticorpos
EP1418235A3 (en) Intracellular domain of the her-2/neu protein for prevention or treatment of maligancies
BR9813373A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente
WO1999064059A3 (en) Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders
MXPA01005545A (es) Composicion y metodo para tratamiento de cancer que usan moduladores de transduccion de senales y aceites esenciales vegetales naturales.
WO2000015205A3 (en) Use of acetylcholinesterase inhibitors for the preparation of pharmaceutical compositions for the treatment of functional and/or organic pain syndromes
FI972433A0 (fi) Rantes-peptidi ja fragmentteja sekä tätä sisältäviä tulehduksen hoitoon soveltuvia koostumuksia
WO1999058674A3 (en) Method of inhibiting osteoclast activity
EP0824915A3 (de) Herstellung von Glycoglycerolipiden, deren Verwendung als Tenside sowie kosmetische oder dermatologische Zubereitungen, solche Glycoglycerolipide enthaltend
US3463862A (en) Albumin containing comsmetic lotion
ES2120585T3 (es) Composicion cosmetica o farmaceutica anti radicales libres para aplicacion topica.
MX9603596A (es) Perfluoropolieteres o composiciones de los mismos para prevencion y tratamiento de infecciones virales topicas.
BR9708928A (pt) Tratamento de asma com tnfr-ig
FR2679134B1 (fr) Compositions cosmetiques pour la regulation de la pigmentation cutanee comprenant un extrait d&#39;eclipta alba.
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
FR2792831B1 (fr) Composition a destination cosmetique et/ou dietetique comprenant un melange de lycopene et d&#39;extrait de feuille d&#39;olivier
WO1996022305A3 (en) Modified peptides
WO1999013819A3 (en) Composition and method for reducing stinging in skin
AU617036B2 (en) Phenylhydrazones, the manufacture thereof and therapeutic and cosmetic compositions prepared therefrom
DE69816808D1 (de) Somatostatin agoniste zur reduzierung von körpergewicht
EP0743068A3 (en) Composition for inhibiting bone loss containing vanadyl sulfate

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
B09B Patent application refused [chapter 9.2 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C07K 14/715 (2006.01), A61K 47/68 (2017.0